Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Division of Genetics and Development, Children's Health Research Institute, Lawson Research Institute, London, Ontario, Canada.
Mol Cell Biol. 2020 Aug 28;40(18). doi: 10.1128/MCB.00189-20.
Precursor B cell acute lymphoblastic leukemia (B-ALL) is caused by genetic lesions in developing B cells that function as drivers for the accumulation of additional mutations in an evolutionary selection process. We investigated secondary drivers of leukemogenesis in a mouse model of B-ALL driven by PU.1/Spi-B deletion (Mb1-CreΔPB). Whole-exome-sequencing analysis revealed recurrent mutations in (encoding Janus kinase 3), , and (encoding Aiolos). Mutations with a high variant-allele frequency (VAF) were dominated by C→T transition mutations that were compatible with activation-induced cytidine deaminase, whereas the majority of mutations, with a low VAF, were dominated by C→A transversions associated with 8-oxoguanine DNA damage caused by reactive oxygen species (ROS). The Janus kinase (JAK) inhibitor ruxolitinib delayed leukemia onset, reduced ROS and ROS-induced gene expression signatures, and altered ROS-induced mutational signatures. These results reveal that JAK mutations can alter the course of leukemia clonal evolution through ROS-induced DNA damage.
前体 B 细胞急性淋巴细胞白血病(B-ALL)是由发育中的 B 细胞中的遗传病变引起的,这些病变作为驱动因素,在进化选择过程中积累额外的突变。我们在由 PU.1/Spi-B 缺失(Mb1-CreΔPB)驱动的 B-ALL 小鼠模型中研究了白血病发生的次要驱动因素。全外显子组测序分析显示, 在 (编码 Janus 激酶 3)、 、 和 (编码 Aiolos)中存在反复出现的突变。高变异等位基因频率(VAF)的突变主要是 C→T 转换突变,与激活诱导的胞嘧啶脱氨酶相容,而大多数低 VAF 的突变主要是 C→A 颠换,与活性氧(ROS)引起的 8-氧鸟嘌呤 DNA 损伤有关。Janus 激酶(JAK)抑制剂鲁索利替尼延迟了白血病的发病,降低了 ROS 和 ROS 诱导的基因表达特征,并改变了 ROS 诱导的突变特征。这些结果表明,JAK 突变可以通过 ROS 诱导的 DNA 损伤改变白血病克隆进化的过程。